Mark Pasmantier

6.1k total citations · 1 hit paper
36 papers, 4.2k citations indexed

About

Mark Pasmantier is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Mark Pasmantier has authored 36 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Mark Pasmantier's work include Lung Cancer Diagnosis and Treatment (16 papers), Lung Cancer Treatments and Mutations (13 papers) and Radiomics and Machine Learning in Medical Imaging (11 papers). Mark Pasmantier is often cited by papers focused on Lung Cancer Diagnosis and Treatment (16 papers), Lung Cancer Treatments and Mutations (13 papers) and Radiomics and Machine Learning in Medical Imaging (11 papers). Mark Pasmantier collaborates with scholars based in United States, Canada and Israel. Mark Pasmantier's co-authors include Daniel M. Libby, David F. Yankelevitz, Claudia I. Henschke, James P. Smith, Nasser K. Altorki, Dorothy I. McCauley, Olli S. Miettinen, Georgeann McGuinness, David P. Naidich and June H. Koizumi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Mark Pasmantier

35 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Lung Cancer Action Project: overall design and findings from baseline screening

1999 1.9k citations Claudia I. Henschke, Dorothy I. McCauley et al. The Lancet profile →

Peers

Countries citing papers authored by Mark Pasmantier

Since Specialization

Citations

This map shows the geographic impact of Mark Pasmantier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Pasmantier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Pasmantier more than expected).

Fields of papers citing papers by Mark Pasmantier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Pasmantier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Pasmantier. The network helps show where Mark Pasmantier may publish in the future.

Co-authorship network of co-authors of Mark Pasmantier

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Pasmantier. A scholar is included among the top collaborators of Mark Pasmantier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Pasmantier. Mark Pasmantier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lung Cancers Diagnosed at Annual CT Screening: Volume Doubling Times 2012 ·Radiology ·Claudia I. Henschke, David F. Yankelevitz, Rowena Yip, Anthony P. Reeves, Ali Farooqi, Dongming Xu, James P. Smith, Daniel M. Libby, Mark Pasmantier, Olli S. Miettinen	159
2	Emphysema Scores Predict Death From COPD and Lung Cancer 2011 ·CHEST Journal ·Javier J. Zulueta, Juan P. Wisnivesky, Claudia I. Henschke, Rowena Yip, Ali Farooqi, Dorothy I. McCauley, (unknown), Daniel M. Libby, James P. Smith, Mark Pasmantier, David F. Yankelevitz	125
3	Ordinal Scoring of Coronary Artery Calcifications on Low-Dose CT Scans of the Chest is Predictive of Death from Cardiovascular Disease 2010 ·Radiology ·Joseph Shemesh, Claudia I. Henschke, Dorith Shaham, Rowena Yip, Ali Farooqi, Matthew D. Cham, Dorothy I. McCauley, (unknown), James P. Smith, Daniel M. Libby, Mark Pasmantier, David F. Yankelevitz	228
4	Chemotherapy Significantly Increases the Risk of Radiation Pneumonitis in Radiation Therapy of Advanced Lung Cancer 2010 ·American Journal of Clinical Oncology ·B. Parashar, Alison Edwards, Rajeev Mehta, Mark Pasmantier, A. Gabriella Wernicke, Albert Sabbas, (unknown), Dattatreyudu Nori, K Chao	46
5	CT Screening for Lung Cancer 2006 ·CHEST Journal ·Daniel M. Libby, Ning Wu, Injae Lee, Ali Farooqi, James P. Smith, Mark Pasmantier, Dorothy I. McCauley, David F. Yankelevitz, Claudia I. Henschke	48
6	Managing the Small Pulmonary Nodule Discovered by CT 2004 ·CHEST Journal ·Daniel M. Libby, James P. Smith, Nasser K. Altorki, Mark Pasmantier, David F. Yankelevitz, Claudia I. Henschke	155
7	CT Screening for Lung Cancer: Suspiciousness of Nodules according to Size on Baseline Scans 2004 ·Radiology ·Claudia I. Henschke, David F. Yankelevitz, David P. Naidich, Dorothy I. McCauley, Georgeann McGuinness, Daniel M. Libby, James P. Smith, Mark Pasmantier, Olli S. Miettinen	261
8	Tumor Size Predicts Survival Within Stage IA Non-Small Cell Lung Cancer * 2003 ·CHEST Journal ·Jeffrey L. Port, Michael S. Kent, Robert J. Korst, Daniel M. Libby, Mark Pasmantier, Nasser K. Altorki	130
9	Overdiagnosis in chest radiographic screening for lung carcinoma 2003 ·Cancer ·David F. Yankelevitz, William J. Kostis, Claudia I. Henschke, Robert T. Heelan, Daniel M. Libby, Mark Pasmantier, James P. Smith	86
10	Guidelines for the use of spiral computed tomography in screening for lung cancer 2003 ·European Respiratory Journal ·Claudia I. Henschke, David F. Yankelevitz, Dorothy I. McCauley, Daniel M. Libby, Mark Pasmantier, James P. Smith	16
11	Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial 2003 ·Journal of Thoracic and Cardiovascular Surgery ·Roger Keresztes, Jeffrey L. Port, Mark Pasmantier, (unknown), Nasser K. Altorki	18
12	Computed tomography screening for lung cancer 2002 ·Clinics in Chest Medicine ·Claudia I. Henschke, David F. Yankelevitz, Daniel M. Libby, Dorothy I. McCauley, Mark Pasmantier, James P. Smith	5
13	Early Lung Cancer Action Project 2001 ·Annals of the New York Academy of Sciences ·Claudia I. Henschke, David F. Yankelevitz, Daniel M. Libby, Dorothy I. McCauley, Mark Pasmantier, Nasser K. Altorki, James P. Smith, Olli S. Miettinen	48
14	Early Lung Cancer Action Project: A Summary of the Findings on Baseline Screening 2001 ·The Oncologist ·Claudia I. Henschke, Dorothy I. McCauley, David F. Yankelevitz, David P. Naidich, Georgeann McGuinness, Olli S. Miettinen, Daniel M. Libby, Mark Pasmantier, June H. Koizumi, Nasser K. Altorki, James P. Smith	108
15	Early Lung Cancer Action Project: overall design and findings from baseline screening breakdown → 1999 ·The Lancet ·Claudia I. Henschke, Dorothy I. McCauley, David F. Yankelevitz, David P. Naidich, Georgeann McGuinness, Olli S. Miettinen, Daniel M. Libby, Mark Pasmantier, June H. Koizumi, Nasser K. Altorki, James P. Smith	1871
16	The Effect of Surgical Debulking on the Response of Patients with Ovarian Carcinoma to Chemotherapy 1988 ·American Journal of Clinical Oncology ·David F. McDermott, Eric Jaffe, Morton Coleman, Mark Pasmantier	0
17	Advances in chemotherapy for large cell lymphoma. 1987 ·PubMed ·Morton Coleman, (unknown), (unknown), (unknown), (unknown), (unknown), R T Silver, Mark Pasmantier	36
18	HAC-cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating Chemotherapy With Intensification 1985 ·Cancer ·Morton Coleman, Mark Pasmantier, Richard T. Silver	7
19	Morbidity of staging laparotomy in Hodgkin's disease 1978 ·The American Journal of Medicine ·Stuart Brogadir, (unknown), Morton Coleman, Vincent Vinciguerra, Thomas J. Degnan, Mark Pasmantier, Richard T. Silver	25
20	High dose methotrexate with citrovorum factor in adult resistant lymphoma 1977 ·Cancer ·(unknown), Morton Coleman, Richard T. Silver, Mark Pasmantier	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact